Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NIBR3049 |
Synonyms | |
Therapy Description |
NIBR3049 is a selective ATP-competitive inhibitor of JAK3 (PMID: 25217444). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NIBR3049 | TCS 21311 | JAK3 Inhibitor - ATP competitive 4 | NIBR3049 is a selective ATP-competitive inhibitor of JAK3 (PMID: 25217444). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK3 L857P | Advanced Solid Tumor | sensitive | NIBR3049 | Preclinical - Cell culture | Actionable | In a preclinical study, NIBR3049 inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing JAK3 L857P in culture (PMID: 26446793). | 26446793 |
JAK3 V674A | Advanced Solid Tumor | decreased response | NIBR3049 | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells over expressing JAK3 V674A demonstrated reduced sensitivity to NIBR3049 in culture (PMID: 26446793). | 26446793 |
JAK3 Y100A JAK3 L857P | Advanced Solid Tumor | sensitive | NIBR3049 | Preclinical - Cell culture | Actionable | In a preclinical study, NIBR3049 inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing both JAK3 L857P and Y100A in culture (PMID: 26446793). | 26446793 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|